Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

160
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
160
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

12
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
12
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

21
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
21
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

159
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
159

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of acid solutions at different concentrations on ciliary cells in eustachian tube mucosa of rats.

Hearing research·2026
Same author

Sotagliflozin improves cognitive deficits and attenuates neuroinflammation of Alzheimer's disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Hippocampal C5a-C5aR1 axis drives age-related memory decline via collapsing synaptic chloride homeostasis.

Brain, behavior, and immunity·2026
Same author

Amyloid beta aggregation seeding activity as a new biomarker for Alzheimer's disease.

Chinese medical journal·2026
Same author

Comparative performance of semi-quantitative methods for amyloid deposition in preclinical autosomal dominant Alzheimer's disease.

Alzheimer's research & therapy·2026
Same author

Plasma biomarker trajectories across Alzheimer's clinical onset: a 17-year prospective study.

Alzheimer's research & therapy·2026

Related Experiment Video

Updated: Jul 23, 2025

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

371

Post-COVID cognitive dysfunction: current status and research recommendations for high risk population.

Meina Quan1,2, Xuechu Wang1, Min Gong1

  • 1Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, China.

The Lancet Regional Health. Western Pacific
|July 17, 2023
PubMed
Summary

Post-COVID cognitive dysfunction (PCCD) involves cognitive impairment after SARS-CoV-2 infection. Research is needed to identify risk factors and develop effective prevention and management strategies for this condition.

Keywords:
DiagnosisEpidemiologyLong COVIDManagementPost-COVID cognitive dysfunctionRisk factors

More Related Videos

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.0K
Author Spotlight: Rehabilitation of Stroke Patients With a Digital Occupational Training System
07:35

Author Spotlight: Rehabilitation of Stroke Patients With a Digital Occupational Training System

Published on: December 29, 2023

1.3K

Related Experiment Videos

Last Updated: Jul 23, 2025

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

371
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.0K
Author Spotlight: Rehabilitation of Stroke Patients With a Digital Occupational Training System
07:35

Author Spotlight: Rehabilitation of Stroke Patients With a Digital Occupational Training System

Published on: December 29, 2023

1.3K

Area of Science:

  • Neurology
  • Infectious Diseases
  • Public Health

Background:

  • Post-COVID cognitive dysfunction (PCCD) is a significant neurological complication following SARS-CoV-2 infection.
  • Characterized by impaired cognitive function across multiple domains, PCCD presents approximately three months post-infection and is not attributable to other diagnoses.
  • Current understanding of PCCD's risk factors and management remains limited, necessitating a consolidated approach to its study.

Purpose of the Study:

  • To review and synthesize current evidence on the epidemiology, diagnostic markers, risk factors, and treatments for PCCD.
  • To establish consensus criteria for better understanding and management of PCCD.
  • To develop a research recommendation framework for identifying and supporting vulnerable populations affected by PCCD.

Main Methods:

  • Comprehensive literature review of studies on Post-COVID cognitive dysfunction.
  • Analysis of epidemiological data, diagnostic markers, and identified risk factors.
  • Evaluation of existing treatment strategies and formulation of management recommendations.

Main Results:

  • The review synthesizes available data on PCCD, highlighting gaps in knowledge regarding its etiology and progression.
  • Identified key risk factors and vulnerable populations requiring further investigation.
  • Summarized current therapeutic approaches and their limitations.

Conclusions:

  • PCCD is a recognized post-infectious neurological condition requiring further research for effective management.
  • Consensus criteria and targeted research frameworks are essential for advancing the understanding and treatment of PCCD.
  • Addressing PCCD is crucial for improving patient outcomes in the post-COVID era.